Neumann J, et al. - Researchers here analyzed CDX2 expression in correlation with overall (OS) and progression-free survival (PFS) considering metastatic disease, mismatch repair (MMR) deficiency, and the mutational status of BRAF to be important prognostic determinants in colorectal cancer (CRC). Both cohorts [a study cohort of 503 CRC specimens (FIRE-3) and a matched case-control collection of 50 right-sided CRC specimens with synchronous distant metastases and 50 right-sided CRCs without distant metastases] showed a significant correlation of CDX2 expression and MMR deficiency, as well as the presence of a BRAF mutation, whereas showed no correlation of CDX2 expression and synchronous metastasis. In the case-control study, only patients with proficient MMR status showed a correlation of CDX2 loss and synchronous metastasis, whereas in patients with deficient MMR status and CDX2 loss, no distant metastases at the time of diagnosis were observed. Data thereby suggest that the prognostic impact of CDX2 depends on the MMR status and the BRAF mutational status of the tumors. Thus, CDX2 was not noted to be an independent prognostic biomarker in CRC.